APA (7th ed.) Citation

Nyirjesy, P., Schwebke, J. R., Angulo, D. A., Harriott, I. A., Azie, N. E., & Sobel, J. D. (2022). Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. Clinical Infectious Diseases, 74(12), 2129. https://doi.org/10.1093/cid/ciab841

Chicago Style (17th ed.) Citation

Nyirjesy, Paul, Jane R. Schwebke, David A. Angulo, Itzel A. Harriott, Nkechi E. Azie, and Jack D. Sobel. "Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis." Clinical Infectious Diseases 74, no. 12 (2022): 2129. https://doi.org/10.1093/cid/ciab841.

MLA (9th ed.) Citation

Nyirjesy, Paul, et al. "Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis." Clinical Infectious Diseases, vol. 74, no. 12, 2022, p. 2129, https://doi.org/10.1093/cid/ciab841.